Contact us Demo our platform

Case Study

Circulating Lipids as COVID-19 Inflammatory Markers

The study’s findings demonstrate the potential of serum lipidomics to characterize the previously underappreciated role that lipids play in injury-induced acute critical illness.

The results of the Metabolon Complex Lipids Targeted Panel revealed mechanisms contributing to worsened outcomes for patients hospitalized for acute critical illness.

Talk With An Expert About Your Project

The results of the Metabolon Complex Lipids Panel produced mechanisms contributing to worsened outcomes for patients hospitalized for acute critical illness. 

Talk With An Expert About Your Project
Circulating Lipids as COVID-19 Inflammatory Markers

The Challenge: What Role do Lipids Play in Inflammatory Signaling During Acute Critical Illness?

Severe injury and infections, common causes of acute critical illness like COVID-19, are among the leading causes of death worldwide.1 Regardless of the cause, disturbances to the inflammatory response represent an important contributor to acute critical illness.2,3 While proteins mediate much of the inflammatory response, lipids also play an important role in systemic inflammation. This class of biomolecule acts as an important energy source for cells and also acts as signaling molecules for the immune response.4 Although lipids contribute to immune system responses, their role in the progression of acute illness has not been fully elucidated.

A recent clinical study—the Prehospital Air Medical Plasma (PAMPer) Trial—determined that administering thawed allogeneic plasma (TP) to injured patients at risk for hemorrhagic shock improved 30-day survival after admission.5 Despite its potential benefits, standard-of-care procedures still do not include TP in pre-hospital settings. Hence, the role that circulating lipids play and the mechanisms that underlie TP-derived clinical improvements in acute critical illness require further exploration as well.

The Solution: Monitor the Sera of Acute Critical Illness Patients

Observing the inflammatory response in patients with acute critical illness remains a challenge. In many cases, the moment a patient is hospitalized does not represent the time of critical disease onset.3 To alleviate this issue, the researchers established a biobank from the PAMPer study to profile circulating biomolecules.6 By monitoring acutely injured patients, the PAMPer study creates an opening to examine injury-specific inflammatory responses in otherwise healthy patients.

In this study, published in Nature Communications, the researchers first divided the patients into two groups. One group of 84 patients was provided with two units of TP while the control group of 109 patients was given standard of care alone. A separate group of 17 healthy volunteers also had their plasma collected as baseline controls. From these patients, the PAMPer biobank was generated. Blood samples were collected upon admission, 24 hours after admission, and 72 hours after admission. As the study progressed, the patients were then stratified into three groups: those that didn’t survive, others who survived but failed to resolve, and those who recovered.

Metabolon Insight: Untargeted Lipidomics Identifies Fatty Acids as Biomarkers Associated with Worse Outcomes

After collecting plasma from the patient population, the researchers used the Metabolon Complex Lipids Targeted Panel to generate lipid-based profiles as patients underwent their respective treatment procedures. Initial liquid chromatography-mass spectrometry (LC-MS) efforts with this panel yielded 996 quantifiable lipids across all patients. The researchers then found that the total abundance of these lipids was significantly lower among the non-survivors within the first day of treatment than the healthy controls and non-resolving patients. TP treatment increased patient survival and also restored lipid levels to those similar to healthy controls.

The concentrations of a subset of lipids also increased among non-resolving survivors within 72 hours. Most notably, the authors observed an increased abundance of phosphatidylethanolamines (PE) and ceramides (CER) after 72 hours of treatment among these patients. To dive further into the role of ceramides, Metabolon offers the Sphingolipids Targeted Panel, not used in this study. Based on the trends observed from the lipidomics study results, the researchers generated a lipid reprogramming score (LRS) to predict instances of worse outcomes for acute critical illness patients. LRS was successful, being strongly prognostic for worsened clinical outcomes among acute trauma and COVID-19 patients.

The Outcome: Lipidomics is Prognostic for Acute Critical Illness Progression

The results of the Metabolon Complex Lipids Targeted Panel produced mechanisms contributing to worsened outcomes for patients hospitalized for acute critical illness. For one, the benefits that TP produces for patients hospitalized for acute critical illness may stem from lipids that minimize the risk of an excessive inflammatory response. The findings also reveal the dynamic nature of inflammation in acute critical illness. Within 72 hours of admission, the levels of a subset of fatty acids increased among non-recovering patients. This observation is reminiscent of findings implicating ongoing liver-driven systemic inflammation and metabolic stress in acute critical illness.7,8 With LRS developed, the study provides an opportunity to investigate more deeply the role that circulating fatty acids play in acute critical illness. The findings from that work will provide further insights into using TP and other treatment options to manage and treat acute critical illness.

References

1. Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1151-1210. doi:10.1016/S0140-6736(17)32152-9

2. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208(13):2581-2590. doi:10.1084/jem.20111354

3. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407-420. doi:10.1038/nri.2017.36

4. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9(2):162-176. doi:10.1038/nrm2335

5. Sperry JL, Guyette FX, Brown JB, et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. New England Journal of Medicine. 2018;379(4):315-326. doi:10.1056/NEJMoa1802345

6. Wu J, Cyr A, Gruen DS, et al. Lipidomic signatures align with inflammatory patterns and outcomes in critical illness. Nat Commun. 2022;13(1):6789. Published 2022 Nov 10. doi:10.1038/s41467-022-34420-4

7. Jeschke MG. The hepatic response to thermal injury: is the liver important for postburn outcomes? Mol Med. 2009;15(9-10):337-351. doi:10.2119/molmed.2009.00005

8. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020;33(11):2147-2155. doi:10.1038/s41379-020-00649-x

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.